WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010030396) NOVEL SHRNA GENE THERAPY FOR TREATMENT OF ISCHEMIC HEART DISEASE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/030396    International Application No.:    PCT/US2009/005147
Publication Date: 18.03.2010 International Filing Date: 15.09.2009
IPC:
C07H 21/00 (2006.01), A61K 31/7088 (2006.01), A61P 9/00 (2006.01)
Applicants: STANFORD UNIVERSITY [US/US]; Office of Technology Licensing 1705 El Camino Real Palo Alto, CA 94306-1106 (US) (For All Designated States Except US).
WU, Joseph, C. [US/US]; (US) (For US Only).
GIACCIA, Amato, John [US/US]; (US) (For US Only).
HUANG, Mei [US/US]; (US) (For US Only).
CHAN, Denise, A. [US/US]; (US) (For US Only)
Inventors: WU, Joseph, C.; (US).
GIACCIA, Amato, John; (US).
HUANG, Mei; (US).
CHAN, Denise, A.; (US)
Agent: BEAUMONT, William, E.; The Nath Law Group 112 S. West Street Alexandria, VA 22314 (US)
Priority Data:
61/136,555 15.09.2008 US
Title (EN) NOVEL SHRNA GENE THERAPY FOR TREATMENT OF ISCHEMIC HEART DISEASE
(FR) NOUVELLE THÉRAPIE GÉNIQUE PAR ARNSH POUR TRAITER UNE CARDIOPATHIE ISCHÉMIQUE
Abstract: front page image
(EN)Short hairpin RNA (shRNA) interference therapy targeting hypoxia inducible factor- lot (HIF-1 α) prolyl-4-hydroxylase protein (HIF-PHD2) is used for treatment of myocardial ischemia. This treatment can be followed noninvasively by molecular imaging. Provided are compositions comprising novel vectors encoding shRNA targeting the HIF-1α and asparaginyl hydroxylase genes. The vectors encoding shRNA are also useful for the treatment of cardiac diseases, peripheral vascular diseases and decubitis ulcers.
(FR)On utilise une thérapie par interférence de petits ARN en épingle à cheveux (ARNsh) ciblant une protéine prolyl hydroxylase (HIF-PHD2)facteur alpha (HIF-1α) inductible par hypoxie pour traiter une ischémie myocardiale. Ce traitement peut être suivi d'une imagerie moléculaire non invasive. L'invention concerne également des compositions comprenant de nouveaux vecteurs qui codent pour l'ARNsh ciblant HIF-1α et des gènes d'asparaginyl hydrolase. Les vecteurs codant pour un ARNsh sont utilisés pour traiter les maladies cardio-vasculaires, les maladies vasculaires périphériques et les escarres de décubitus.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)